Skip to content

The Efficacy of Broad-spectrum Comprehensive Light Therapy for Complex Regional Pain Syndrome Type I after Stroke

The Efficacy of Broad-spectrum Comprehensive Light Therapy for Complex Regional Pain Syndrome Type I after Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057624
Enrollment
Unknown
Registered
2022-03-15
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndrome Type I after Stroke

Interventions

Experimental group:Broad-spectrum Comprehensive Light Therapy and Conventional Rehabilitation
Control group:Conventional Rehabilitation

Sponsors

Wuhan Wuchang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria for stroke: formulated according to "Key Diagnostic Criteria for Various Cerebrovascular Diseases" of the Fourth National Conference on Cerebrovascular Diseases of the Chinese Neurological Association. And the first stroke after hemiplegia, the course of the disease within 12 months; 2. In the early or middle stages of complex regional pain syndrome type I; 3. The MMSE score was higher than 23.

Exclusion criteria

Exclusion criteria: 1. Unstable medical conditions; 2. Visually impaired; 3. Shoulder subluxation; 4. History of shoulder injection within the past 6 months; 5. There is to ignore; 6. There are other causes of upper limb pain; 7. With progressive central nervous system disorders; 8. History of hand dysfunction on the affected side; 9. Complicated with malignant tumor, systemic infection, dysfunction of important organs and other major diseases.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale(VAS);

Secondary

MeasureTime frame
Brunnstrom Rating Scales;Fugl-Meyer Assessment Upper Extremity (FMA-UE);Functional Independent Measurement of Motion Items;Modified Ashworth Scale (MAS);Calcitonin Gene-Related Peptide (CGRP);Endothelin-1;Bradykinin;

Countries

China

Contacts

Public ContactTangzhu Yang

Wuhan Wuchang Hospital

258582639@qq.com+86 18627071976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026